Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)

SHA:688621 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,055	1,077	930.98	676.39	492.86	346.82
Other Revenue	1.61	1.61	1.14	0.21	0.79	0.54
Revenue	1,057	1,078	932.12	676.61	493.65	347.36
Revenue Growth (YoY)	11.04%	15.70%	37.76%	37.06%	42.12%	48.74%
Cost of Revenue	558.7	537.33	403.77	301.15	229.97	175.02
Gross Profit	498.35	541.14	528.35	375.46	263.68	172.33
Selling, General & Admin	149.72	150.44	153.24	110.81	85.63	52.87
Research & Development	174.71	171.94	123.68	89.69	47.58	34.19
Other Operating Expenses	-1.58	0.76	0.2	0.16	0.04	0.04
Operating Expenses	373.15	364.82	334.89	219.32	143.72	90.16
Operating Income	125.19	176.32	193.46	156.14	119.97	82.17
Interest Expense	-15.2	-16.11	-12.18	-9.7	-3.56	-1.04
Interest & Investment Income	4.96	5.67	8.53	8.78	2.52	0.63
Other Non Operating Income (Expenses)	-2.77	-2.66	-2.47	-0.96	-0.72	0.26
EBT Excluding Unusual Items	112.18	163.22	187.35	154.25	118.21	82.02
Gain (Loss) on Sale of Investments	-1.82	-1.82	-	-	-	-
Gain (Loss) on Sale of Assets	-0.31	-0.31	-0.71	-0.25	-0.51	-0.08
Other Unusual Items	14.9	14.9	6.76	15.14	4.4	0.34
Pretax Income	124.95	175.99	193.4	169.14	122.1	82.28
Income Tax Expense	-2.67	6.97	10.5	10.43	13.31	8.12
Earnings From Continuing Operations	127.62	169.01	182.9	158.7	108.79	74.16
Minority Interest in Earnings	6.61	8.4	1.86	-2.23	-3.13	-1.7
Net Income	134.23	177.41	184.76	156.47	105.66	72.46
Net Income to Common	134.23	177.41	184.76	156.47	105.66	72.46
Net Income Growth	-35.95%	-3.98%	18.08%	48.09%	45.81%	52.88%
Shares Outstanding (Basic)	112	112	112	112	98	84
Shares Outstanding (Diluted)	112	112	112	112	98	84
Shares Change (YoY)	0.40%	0.28%	0.19%	14.09%	16.84%	-0.19%
EPS (Basic)	1.20	1.58	1.65	1.40	1.08	0.86
EPS (Diluted)	1.20	1.58	1.65	1.40	1.08	0.86
EPS Growth	-36.21%	-4.24%	17.86%	29.80%	24.80%	53.16%
Free Cash Flow	19.62	1.54	19.9	0.09	3.29	35.96
Free Cash Flow Per Share	0.17	0.01	0.18	0.00	0.03	0.43
Dividend Per Share	0.163	0.163	0.165	0.429	0.189	-
Dividend Growth	-1.21%	-1.21%	-61.50%	126.41%	-	-
Gross Margin	47.14%	50.18%	56.68%	55.49%	53.41%	49.61%
Operating Margin	11.84%	16.35%	20.76%	23.08%	24.30%	23.66%
Profit Margin	12.70%	16.45%	19.82%	23.13%	21.40%	20.86%
Free Cash Flow Margin	1.86%	0.14%	2.14%	0.01%	0.67%	10.35%
EBITDA	151.41	201.69	215.47	173.19	131.47	91.78
EBITDA Margin	14.32%	18.70%	23.12%	25.60%	26.63%	26.42%
D&A For EBITDA	26.22	25.38	22.01	17.05	11.5	9.61
EBIT	125.19	176.32	193.46	156.14	119.97	82.17
EBIT Margin	11.84%	16.35%	20.76%	23.08%	24.30%	23.66%
Effective Tax Rate	-	3.96%	5.43%	6.17%	10.90%	9.87%
Revenue as Reported	1,057	1,078	932.12	676.61	493.65	347.36
Advertising Expenses	-	0.58	1.69	1.17	1.13	0.79

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.